EL.En Valuation
Is ELN undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
3/6Valuation Score 3/6
Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of ELN when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: ELN (€12.01) is trading above our estimate of fair value (€6.96)
Significantly Below Fair Value: ELN is trading above our estimate of fair value.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for ELN?
Key metric: As ELN is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.
| What is ELN's PE Ratio? | |
|---|---|
| PE Ratio | 18.8x |
| Earnings | €51.18m |
| Market Cap | €961.63m |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 1.4x |
| Enterprise Value/EBITDA | 12.4x |
| PEG Ratio | 2.4x |
Price to Earnings Ratio vs Peers
How does ELN's PE Ratio compare to its peers?
| Company | Forward PE | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 25.1x | ||
DIA DiaSorin | 29.5x | 13.6% | €5.6b |
IMD I.M.D. International Medical Devices | 9.9x | 18.6% | €25.6m |
GHC Garofalo Health Care | 24.1x | 11.0% | €504.8m |
GPI GPI | 36.8x | 35.2% | €329.0m |
ELN EL.En | 18.8x | 8.0% | €961.6m |
Price-To-Earnings vs Peers: ELN is good value based on its Price-To-Earnings Ratio (18.8x) compared to the peer average (25.1x).
Price to Earnings Ratio vs Industry
How does ELN's PE Ratio compare vs other companies in the European Medical Equipment Industry?
| 3 Companies | Price / Earnings | Estimated Growth | Market Cap |
|---|---|---|---|
| 3 Companies | Estimated Growth | Market Cap | |
|---|---|---|---|
Price-To-Earnings vs Industry: ELN is good value based on its Price-To-Earnings Ratio (18.8x) compared to the European Medical Equipment industry average (28.9x).
Price to Earnings Ratio vs Fair Ratio
What is ELN's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PE Ratio | 18.8x |
| Fair PE Ratio | 19.8x |
Price-To-Earnings vs Fair Ratio: ELN is good value based on its Price-To-Earnings Ratio (18.8x) compared to the estimated Fair Price-To-Earnings Ratio (19.8x).
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
| Date | Share Price | Average 1Y Price Target | Dispersion | High | Low | 1Y Actual price | Analysts |
|---|---|---|---|---|---|---|---|
| Current | €12.01 | €13.10 +9.1% | 1.1% | €13.30 | €13.00 | n/a | 3 |
| Nov ’25 | €10.22 | €11.90 +16.4% | 11.7% | €13.30 | €10.00 | n/a | 3 |
| Oct ’25 | €10.60 | €11.90 +12.3% | 11.7% | €13.30 | €10.00 | n/a | 3 |
| Sep ’25 | €10.36 | €12.03 +16.2% | 12.1% | €13.30 | €10.00 | n/a | 3 |
| Aug ’25 | €9.54 | €12.03 +26.1% | 12.1% | €13.30 | €10.00 | n/a | 3 |
| Jul ’25 | €9.37 | €12.03 +28.4% | 12.1% | €13.30 | €10.00 | n/a | 3 |
| Jun ’25 | €10.06 | €12.03 +19.6% | 12.1% | €13.30 | €10.00 | n/a | 3 |
| May ’25 | €11.83 | €12.23 +3.4% | 13.0% | €13.60 | €10.00 | n/a | 3 |
| Apr ’25 | €11.74 | €12.23 +4.2% | 13.0% | €13.60 | €10.00 | n/a | 3 |
| Mar ’25 | €8.67 | €11.23 +29.6% | 8.2% | €12.20 | €10.00 | n/a | 3 |
| Feb ’25 | €9.09 | €11.23 +23.6% | 8.2% | €12.20 | €10.00 | n/a | 3 |
| Jan ’25 | €9.75 | €11.23 +15.2% | 8.2% | €12.20 | €10.00 | n/a | 3 |
| Dec ’24 | €9.36 | €11.23 +20.1% | 8.2% | €12.20 | €10.00 | n/a | 3 |
| Nov ’24 | €8.69 | €11.83 +36.2% | 7.2% | €13.00 | €11.00 | €10.22 | 3 |
| Oct ’24 | €8.71 | €11.83 +35.9% | 7.2% | €13.00 | €11.00 | €10.60 | 3 |
| Sep ’24 | €10.85 | €14.77 +36.1% | 2.6% | €15.30 | €14.50 | €10.36 | 3 |
| Aug ’24 | €10.74 | €14.77 +37.5% | 2.6% | €15.30 | €14.50 | €9.54 | 3 |
| Jul ’24 | €10.99 | €14.77 +34.4% | 2.6% | €15.30 | €14.50 | €9.37 | 3 |
| Jun ’24 | €10.59 | €14.77 +39.4% | 2.6% | €15.30 | €14.50 | €10.06 | 3 |
| May ’24 | €11.70 | €14.77 +26.2% | 2.6% | €15.30 | €14.50 | €11.83 | 3 |
| Apr ’24 | €12.03 | €14.77 +22.7% | 2.6% | €15.30 | €14.50 | €11.74 | 3 |
| Mar ’24 | €15.79 | €16.97 +7.5% | 8.5% | €19.00 | €15.80 | €8.67 | 3 |
| Feb ’24 | €14.55 | €16.97 +16.6% | 8.5% | €19.00 | €15.80 | €9.09 | 3 |
| Jan ’24 | €14.25 | €16.97 +19.1% | 8.5% | €19.00 | €15.80 | €9.75 | 3 |
| Dec ’23 | €14.80 | €16.97 +14.6% | 8.5% | €19.00 | €15.80 | €9.36 | 3 |
| Nov ’23 | €12.21 | €16.93 +38.7% | 8.7% | €19.00 | €15.70 | €8.69 | 3 |
Analyst Forecast: Target price is less than 20% higher than the current share price.
Discover undervalued companies
Fresenius Medical Care
€12.2b
Provides dialysis and related services for individuals with renal diseases in Germany, North America, and internationally.
1FME
€41.73
7D
4.0%
1Y
16.4%
Garofalo Health Care
€504.8m
Operates healthcare clinics in Italy.
GHC
€5.70
7D
4.4%
1Y
25.3%
Amplifon
€5.3b
Engages in the distribution of hearing solutions and the fitting of customized products that help people rediscover various emotions of sound in Europe, the Middle East, Africa, the Americas, and the Asia Pacific.
AMP
€23.60
7D
-2.3%
1Y
-15.5%